与abciximab的联合治疗减少了急性心肌梗塞中血管学上明显的血栓:一个TIMI 14子研究
C M Gibson1, J A de Lemos, S A Murphy
1Harvard Clinical Research Institute, Boston, Massachusetts, USA.
Circulation
|May 31, 2001
概括
与abciximab的联合治疗显著降低了急性心肌梗塞 (AMI) 患者的血管学上明显的血栓 (AET). 这种降低与改善冠状动脉血流和ST段分辨率有关,支持其在血栓消毒单一治疗中使用.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿布西西马布与血栓抑制剂相结合,可改善急性心肌梗塞 (AMI) 的冠状动脉血流.
- 假设的机制:组合疗法减少了血管学上明显的血栓 (AET) 并增加了流层直径,而不是血栓解压单一疗法.
研究的目的:
- 评估abciximab联合治疗对AMI患者AET和光圈直径的影响.
- 为了比较组合疗法与血栓解毒单一疗法在减少血栓负担.
主要方法:
- 对TIMI 14 (组合疗法,n=732) 与TIMI 4,10A,10B,14 (血栓解压单疗法,n=1662) 的患者进行分析.
- 定量血管造影评估AET和光线直径治疗后90分钟的盲人调查人员.
主要成果:
- 阿布西西马布联合治疗显著降低了AET频率 (26.6%与35.4%,P<0.001).
- 在abciximab组观察到改善的残余直径狭窄和增加的ST段分辨率 (>70%).
- 没有AET与较高的ST段分辨率相关 (37.2%与18.9%,P<0.001).
结论:
- 与abciximab的联合治疗减少了AMI中的AET,导致残留狭窄的减少.
- 减少血栓负担与改善的上心和微血管输液有关.
- 提供了血小板抑制和改善AMI结局之间的病理生理联系.
相关概念视频
Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Acute Coronary Syndrome III: Diagnostic Studies
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...


